In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGI Moves Into Acute Care with Guilford Acquisition

Executive Summary

MGI Pharma Inc.'s recent acquisition of Guilford Pharmaceuticals Inc. should allow the oncology specialist to smoothly branch out into acute care while simultaneously adding support for its most important cancer product. Arguably the biggest deal driver is Guilford's Phase III anesthetic propofol prodrug Aquavan-ironically the same drug which faltered in development earlier in 2005, leading to the latest in a string of disappointments for Guilford, a substantial setback in valuation, and an affordable price tag for MGI.
Advertisement

Related Content

No Dilution Necessary: The Promise of Project Financing
No Dilution Necessary: The Promise of Project Financing
Symphony & Guilford Try Out Project Financing
Symphony & Guilford Try Out Project Financing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel